| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
39 |
| Employees |
68 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-163 |
| Cash Flow (TTM) (Millions $) |
-60 |
| Capital Exp. (TTM) (Millions $) |
14 |
Tcr2 Therapeutics Inc
TCR2 Therapeutics Inc is a biotechnology company specializing in the development of T-cell immunotherapies to treat cancer. Their approach involves using T-cell receptors (TCRs) to enhance the body's immune response against cancer cells. TCR2's therapies are designed to target solid tumors and blood cancers by engineering T-cells to recognize and attack specific tumor antigens. The company is focused on developing next-generation, safe and effective treatments that harness the power of the immune system to eliminate cancer cells.
Company Address: 100 Binney Street Cambridge 2142 MA
Company Phone Number: 949-5200 Stock Exchange / Ticker: NASDAQ TCRR
|
%
1.64%